Sterling Capital Management LLC lifted its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 4.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,219 shares of the company’s stock after acquiring an additional 1,814 shares during the quarter. Sterling Capital Management LLC’s holdings in Eli Lilly and were worth $3,988,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Eli Lilly and by 1.2% in the fourth quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock worth $5,393,119,000 after acquiring an additional 776,893 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Eli Lilly and by 2.7% during the fourth quarter. Franklin Resources Inc. now owns 28,519,524 shares of the company’s stock valued at $2,408,787,000 after buying an additional 754,681 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Eli Lilly and by 16.1% during the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after buying an additional 1,503,918 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Eli Lilly and by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 9,854,964 shares of the company’s stock valued at $830,522,000 after acquiring an additional 406,812 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its holdings in Eli Lilly and by 1.8% in the fourth quarter. UBS Asset Management Americas Inc. now owns 6,636,386 shares of the company’s stock valued at $560,509,000 after acquiring an additional 115,499 shares during the period. Institutional investors own 77.62% of the company’s stock.
LLY has been the topic of a number of recent research reports. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and increased their target price for the company from $85.52 to $115.00 in a report on Friday, January 5th. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 12th. Jefferies Group set a $100.00 target price on Eli Lilly and and gave the company a “buy” rating in a report on Tuesday, January 16th. Goldman Sachs downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and increased their target price for the company from $86.98 to $95.00 in a report on Tuesday, January 16th. Finally, Credit Suisse Group downgraded Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 target price on the stock. in a report on Monday, January 22nd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and a consensus target price of $93.37.
Shares of Eli Lilly and Co (NYSE LLY) opened at $76.53 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32. Eli Lilly and Co has a 1 year low of $73.69 and a 1 year high of $89.09. The stock has a market capitalization of $85,719.58, a PE ratio of 18.28, a P/E/G ratio of 1.43 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last released its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The firm had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. During the same quarter last year, the business posted $0.95 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. analysts forecast that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares in the company, valued at approximately $334,901.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joshua L. Smiley sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $79.20, for a total value of $237,600.00. Following the transaction, the chief financial officer now owns 20,029 shares of the company’s stock, valued at approximately $1,586,296.80. The disclosure for this sale can be found here. Insiders have sold 15,261 shares of company stock valued at $1,225,085 in the last quarter. 0.20% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Sterling Capital Management LLC Buys 1,814 Shares of Eli Lilly and Co (LLY)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://ledgergazette.com/2018/03/23/sterling-capital-management-llc-buys-1814-shares-of-eli-lilly-and-co-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.